glp-1/gip dual agonist lilly LLY -0.60% today as Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 receptor agonist, reduced A1C by an average of 2.2% in a Phase 3 trial of children and adolescents with type 2 diabetes The U.S. Food and Drug

Digital Health & AI: Tech-Supported Models Show Real-World Gains Digital health tools and AI-driven support arent just buzzwordstheyre delivering real results for weight management patients on GLP-1 therapy

In RA animal models, these drugs reduced joint damage and bone erosion, potentially preserving mobility and quality of life for patients

doi: 10.1016/S1474-4422(20)30231-3 [DOI] [PMC free article] [PubMed] [Google Scholar] 11

Cost-Effective Solutions : Our compounded medications are priced competitively to ensure they remain accessible

However, the impact on fibrosis improvement was less consistent, with no significant differences observed between semaglutide and placebo in some trials

Managing Side Effects: Tracking side effects allows you and your doctor to identify and manage them effectively